Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕÀÌ È¸¿ø»çÀÇ R&D°æÀï·Â °È¸¦ À§ÇØ Çѱ¹À» ºñ·ÔÇØ Àü¼¼°è 30°³±¹ °ÅÁ¡±â°üµé°ú ÀǾàºÐ¾ß ±â¼úÀÌÀü, ¶óÀ̼¾½Ì, °øµ¿¿¬±¸ ÃËÁø µî ±â¼úÇù·Â»ç¾÷À» ÃßÁø, Á¦¾à°èÀÇ °ü½ÉÀÌ ½ò¸®°í ÀÖ´Ù.
Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕ(ÀÌ»çÀå Á¶ÀÇȯ)Àº 13ÀÏ ¿ÀÀü 10½Ã ¼¿ï´ëÇб³ È£¾Ï±³¼öȸ°ü º»°ü 1Ãþ ¿¡¶ß¿Í¸£·ë¿¡¼ Medicon Valley Academy(www.mva.org)ÀÇ ¿î¿µÃ¥ÀÓÀÚ Stig Jørgensen ¹Ú»ç¸¦ Ưº° ÃÊûÇØ “Çѱ¹-½ºÄµð³ªºñ¾Æ ÀǾàºÐ¾ß ±¹Á¦ ±â¼úÀÌÀü/°øµ¿¿¬±¸ Àü·«¼¼¹Ì³ª¸¦ °³ÃÖÇÑ´Ù.
ÀÌ ¼¼¹Ì³ªÀÇ Âü¼®Àڷδ Çؿܱâ°üµé°úÀÇ ±â¼úÀÌÀü, ¶óÀ̼¾½Ì, °øµ¿¿¬±¸ ÃßÁø¿¡ °ü½ÉÀִ ȸ¿ø»ç °ü°èÀÚ·Î Á¦ÇÑÇÑ´Ù.
¸ÞµðÄܺ§¸®´Â µ§¸¶Å©¿Í ½º¿þµ§ 2°³±¹ÀÌ °øµ¿¿î¿µÇÏ°í ÀÖ´Â ºÏÀ¯·´Áö¿ª ÃÖ´ëÀÇ Á¦¾à/BTŬ·¯½ºÅÍ´Ù.
ÀÌ°÷¿£ ¼¼°è ½Å¾à ÆÄÀÌÇÁ¶óÀÎÀÇ 30%ÀÌ»óÀ» º¸À¯ÇÏ°í ´Ù±¹ÀûÁ¦¾à±â¾÷, ½Å¾à°³¹ßº¥Ã³±â¾÷ µî °¢Á¾ R&DÇãºê±â¾÷°ú ´ëÇÐ, ¿¬±¸±â°ü, ÀÓ»ó½ÃÇè±â°ü µî 250¿©°³ R&D±â°üÀÌ ¹ÐÁýÇØ ÀÖ´Ù.
À̹ø ¼¼¹Ì³ª¿¡¼´Â ¸ÞµðÄܹ븮 ¼ÒÀç ±â¾÷, ´ëÇÐ, ¿¬±¸±â°üµé°ú Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕ È¸¿ø»ç°£ Àü·«Àû ÆÄÆ®³Ê½± Çü¼º ¹× ±â¼úÇù·Â¿¡ °üÇÑ Á¢±Ù¹æ¹ý°ú Çѱ¹±â¾÷¿¡ ´ëÇÑ ±âȸ¿ä¼ÒµîÀÌ ´Ù·ç¾îÁú ¿¹Á¤ÀÌ´Ù.
*¼¼¹Ì³ª ÁÖÁ¦ : Çѱ¹-½ºÄµð³ªºñ¾Æ ÀǾàºÐ¾ß ±¹Á¦±â¼úÀÌÀü/¶óÀ̼¾½Ì/°øµ¿¿¬±¸Àü·«(Effective approaches for Korean pharmaceutical companies to make Strategic R&D Alliances with Medicon Valley innovators; companies, universities & research institutions)
- Overview of Medicon Valley & Medicon Valley Academy and its strong points
- Current trends and future vision of pharmaceutical & bio-tech industry in Medicon Valley
- Innovators in Medicon Valley in pharmaceutical area
- Current status of strategic alliances in Medicon Valley
- Korean opportunities for making partnerships with Medicon Valley innovators
- Effective methods for finding partners in Medicon Valley
- Proposal for collaboration